This article was originally published in The Gray Sheet
Executive SummaryFirm's steerable decapolar electrophysiology diagnostic catheter receives FDA market go-ahead, Mogul announces Aug. 21. A limited U.S. launch will take place in four-to-six months, following an upgrade of the firm's manufacturing facility. The 3 Fr catheter will generally be priced 30% below the competition while offering more features and better performance, the privately held San Jose, California firm claims
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.